Phase 3 acne program opens for Sarecycline in the US
- Actavis indicated at the end of 2014 that
it will initiate a Phase 3 program of Sarecycline
- The antibiotic is a dual, narrow-spectrum
antibacterial and potent anti-inflammatory activity, being
developed for the treatment of acne and rosacea
- Shortly before the holidays, two large studies were posted to CTG
- The first study is a 1000 patient US study
comparing Sarecycline (1.5mg/kg once daily po) and placebo.
The primary endpoints will be absolute change in inflammatory
lesions and Investigator Global Assessment at 12wks and will
read out Oct 2015. The second study is an identical study
also being conducted in the US
This alert is from our UpdatesPlus-Acne and Rosacea service. UpdatesPlus offers A unique and affordable combination of information monitoring and expert analysis across 14 therapy areas [further information]
To access our most recent 30 slide report on recent advances in Acne and Rosacea please contact fiona.watts@leaddiscovery.co.uk
0 Comments:
Post a Comment
<< Home